Human Albumin in Cirrhosis & Liver Failure: Practice Review

Chronic liver disease affects 1.5 billion people globally, of whom 18.3% are of Indian origin, indicating a significant liver cirrhosis-related burden in India. Decreased plasma albumin is a major complication in this patient population, with over 75% of decompensated patients having hypoalbuminemia. Albumin administration has shown promise in reducing complications, including infections and renal dysfunction. Beyond volume expansion, albumin exerts pleiotropic effects including antioxidant activity, immunomodulation, and endothelial stabilization. This article explores albumin's potential role in cirrhosis and liver failure as a disease-modifying therapy, not just a supportive fluid.

Albumin in Liver Cirrhosis: Potential Mechanistic Role

Intravenous albumin improves circulatory dysfunction in cirrhosis through dual mechanisms: expanding intravascular volume to enhance cardiac output, while simultaneously increasing systemic vascular resistance via improved albumin function, enhanced antioxidant activity, and decreased nitric oxide synthesis (Figure 1).

Figure 1: Dual Mechanisms of Albumin in Improving Circulatory Dysfunction in Liver Cirrhosis

Albumin in Liver Cirrhosis Outcomes: Review of Clinical Evidence

Albumin on Outcomes in Decompensated Liver Cirrhosis: A meta-analysis of 16 RCTs (n=1,518 cirrhotic patients) evaluated outcomes with and without albumin use. In paracentesis management, albumin significantly reduced the relative risk odds of paracentesis-induced circulatory dysfunction by 74% (R 0.26). Among patients with infections, albumin reduced the relative risk odds of mortality by 54% (OR 0.46), translating to 14% mortality with albumin versus 26% without treatment at three months, and 66% reduction in renal impairment (OR 0.34). In spontaneous bacterial peritonitis specifically, combining albumin with antibiotics reduced in-hospital mortality from 29% to 10%, establishing albumin as an evidence-based intervention for hemodynamic stability and organ preservation in decompensated liver cirrhosis.

Albumin in Overt Hepatic Encephalopathy: Indian Experience: An RCT of 120 Indian cirrhotic patients (70% Child-Pugh Class C) with overt hepatic encephalopathy [HE] (grades 2-4) compared albumin plus lactulose versus lactulose alone. Complete HE reversal was significantly higher with combination therapy (75% vs 53.3%; p=0.03), accompanied by reduced mortality (18.3% vs 31.6%; p=0.04) and shorter hospital stay (6.4±3.4 vs 8.6±4.3 days; p=0.01). Beyond clinical improvement, albumin combination therapy achieved significantly greater reductions in inflammatory cytokines (IL-6: -17.3±4.6 vs -9.4±3.2 pg/mL; IL-18: -33.5±13.4 vs -17.4±11.5 pg/mL; TNF-α: -25.4±7.7 vs -13.7±5.3 pg/mL; all p<0.05) and endotoxin levels (p=0.02), demonstrating albumin's anti-inflammatory and detoxifying mechanisms enhance outcomes in overt hepatic encephalopathy beyond standard ammonia-lowering therapy.

Albumin in Liver Cirrhosis with Ascites: The ANSWER trial, a multicenter randomized study including 431 patients with decompensated cirrhosis and uncomplicated ascites, demonstrated that long-term albumin administration improved 18-month survival compared to standard medical treatment alone (Kaplan-Meier estimates 77% vs 66%; p=0.028), representing a 38% relative reduction in mortality (HR 0.62). Beyond survival benefits, albumin therapy reduced first paracentesis occurrence by 52% (HR 0.48, p<0.0001) with paracentesis incidence rate ratio of 0.46 (95% CI 0.40–0.53), decreased refractory ascites development by 57% (HR 0.43, p<0.0001), and significantly lowered rates of spontaneous bacterial peritonitis (IRR 0.33), hepatorenal syndrome type 1 (IRR 0.39), and severe hepatic encephalopathy (IRR 0.48). Hospital admissions (IRR 0.65) and days spent in hospital (IRR 0.55) were significantly reduced, establishing albumin as disease-modifying therapy in decompensated cirrhosis (Figure 1).

Figure 1. ANSWER Trial: Clinical and Resource Utilization Outcomes. Abbreviations: SMT, standard medical treatment; SBP, spontaneous bacterial peritonitis; HRS, hepatorenal syndrome; HR, hazard ratio.

Real-World Application & Practical Considerations

International consensus and major hepatology societies recommend considering albumin administration in well-defined clinical scenarios with evidence.

Treatment response is best assessed through clinical improvement in hemodynamics, renal function, and ascites control. Routine monitoring helps ensure safe administration, especially with long-term use. 7,8,9,10

Quality Standards & Product Selection

Given cirrhotic patients' immunocompromised state, albumin quality is paramount. Products meeting IQPP and QSEAL standards ensure pathogen safety through rigorous screening and viral inactivation. Hyperoncotic 25% formulations provide greater oncotic effect per volume in fluid-sensitive patients. Closed-system delivery minimizes central line-associated infection risks in vulnerable populations. Product selection should prioritize manufacturing consistency for long-term therapy and practical considerations, including storage stability and contamination prevention during administration.

Key Take-Home Messages

✔ Chronic liver disease affects 1.5 billion people globally with 18.3% of Indian origin, and over 75% of decompensated liver cirrhosis patients have hypoalbuminemia.

✔ Albumin exerts pleiotropic effects including antioxidant activity, endothelial stabilization, and immunomodulation that address systemic inflammation and circulatory dysfunction in decompensated liver cirrhosis.

✔ Clinical evidence demonstrates albumin reduces mortality and complications, with international guidelines recommending albumin for large-volume paracentesis, spontaneous bacterial peritonitis, hepatorenal syndrome, and uncomplicated ascites management.

✔ Albumin products meeting IQPP and QSEAL standards ensure pathogen safety, with hyperoncotic 25% formulations and closed-system delivery minimizing infection risks in immunocompromised cirrhotic populations.

Abbreviations: AGA- American Gastroenterological Association, ACLF - Acute-on-Chronic Liver Failure, AKI - Acute Kidney Injury, APASL - Asian Pacific Association for the Study of the Liver, HE - Hepatic Encephalopathy, HR - Hazard Ratio, HRS - Hepatorenal Syndrome,ICTMG-International Collaboration for Transfusion Medicine Guidelines, IL-6 - Interleukin-6, IL-18 - Interleukin-18, IQPP - International Quality Plasma Program, IRR - Incidence Rate Ratio, LVP - Large-Volume Paracentesis, NO- nitric oxide, OR - Odds Ratio, PVDC - Polyvinylidene Chloride, QSEAL - Quality Standards of Excellence, Assurance, and Leadership, RCT - Randomized Controlled Trial, SBP - Spontaneous Bacterial Peritonitism, SMT - Standard Medical Treatment